Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be "stopped for futility."
Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.
Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.
DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.
Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.
Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.
NetApp (NTAP) "unexpectedly stumbled" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations "muted," Wedbush Securities said Friday in a review of NetApp's earnings overnight.
Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.
Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.
Price: 39.70, Change: -25.33, Percent Change: -38.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。